Integration of immunotherapy into adjuvant therapy for resected non-small-cell lung cancer: ALCHEMIST chemo-IO (ACCIO)

Jacob M. Sands, Sumithra J. Mandrekar, David Kozono, Geoffrey R. Oxnard, Shauna L. Hillman, Dennis A. Wigle, Ramaswamy Govindan, Jennifer Carlisle, Jhanelle Gray, Joseph K. Salama, Luis Raez, Apar Ganti, Nathan Foster, Shakun Malik, Jeffrey Bradley, Karen Kelly, Suresh S. Ramalingam, Thomas E. Stinchcombe

Research output: Contribution to journalArticlepeer-review

Abstract

Non-small-cell lung cancer (NSCLC) causes significant mortality each year. After successful resection of disease stage IB (>4 cm) to IIIA (per AJCC 7), adjuvant platinum-based chemotherapy improves median overall survival and is the standard of care, but many patients still experience recurrence of disease. An adjuvant regimen with greater efficacy could substantially improve outcomes. Pembrolizumab, a programmed cell death-1 inhibitor, has become an important option in the treatment of metastatic NSCLC. ALCHEMIST is a clinical trial platform of the National Cancer Institute that includes biomarker analysis for resected NSCLC and supports therapeutic trials including A081801 (ACCIO), a three-arm study that will evaluate both concurrent chemotherapy plus pembrolizumab and sequential chemotherapy followed by pembrolizumab to standard of care adjuvant platinum-based chemotherapy. Clinical trial registration: NCT04267848 (ClinicalTrials.gov.

Original languageEnglish (US)
Pages (from-to)727-734
Number of pages8
JournalImmunotherapy
Volume13
Issue number9
DOIs
StatePublished - Jun 2021

Keywords

  • adjuvant chemotherapy
  • lung adenocarcinoma
  • lung squamous cell carcinoma
  • NSCLC
  • pembrolizumab

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Fingerprint

Dive into the research topics of 'Integration of immunotherapy into adjuvant therapy for resected non-small-cell lung cancer: ALCHEMIST chemo-IO (ACCIO)'. Together they form a unique fingerprint.

Cite this